CAMBRIA-2

BCT 2302/AZ D8535C00001: CAMBRIA-2

BCT Study Chair:

Nicholas Zdenkowski

The CAMBRIA-2 clinical trial aims to find out if giving a new treatment called camizestrant is better at stopping cancer from coming back compared with the usual endocrine (hormone) treatments such as letrozole, anastrozole, exemestane or tamoxifen.

The CAMBRIA-2 Clinical Trial

CAMBRIA-2 is for men or women who have ER-positive, HER2-negative early breast cancer that has an intermediate or high risk of coming back (recurrence).

Although many patients with ER-positive, HER2-negative early breast cancer may be cured of their disease with surgery (+/- radiotherapy) and endocrine (hormone) treatment (+/- chemotherapy), a significant number of patients will experience breast cancer coming back (recurrence). Recurrence may be due to resistance to endocrine therapy or dormant tumour cells may grow. Therefore, we need endocrine treatments that are more effective, safe, and that patients continue to take for as long as required, to further improve the cure rate.

Camizestrant is a type of endocrine treatment called a ‘selective oestrogen receptor degrader’ (SERD). Camizestrant works by breaking down the oestrogen receptors in cells, and also blocks the oestrogen receptors from being triggered by oestrogen. This prevents ER-positive cancer cells receiving messages to grow and multiply. Camizestrant may help to reduce the chance of cancer coming back.

The purpose of CAMBRIA-2 is to find out if giving camizestrant is better at reducing the chance of cancer from coming back compared with the usual endocrine treatments such as letrozole, anastrozole, exemestane or tamoxifen. The research will also find out more about the side effects, safety and effectiveness of camizestrant.

CAMBRIA-2 will recruit 5500 patients at approximately 700 sites across 40 countries over 3 and a half years. BCT will recruit approximately 225 patients at 25 Australian and 3 New Zealand sites.

dr. nicholas z receives asco merit award + hormone receptor positive trial

Dr Nicholas Zdenkowski is the Study Chair for the CAMBRIA-2 clinical trial.

Early Breast Cancer
Metastatic
Prevention

PARTICIPATE IN THE CAMBRIA-2 CLINICAL TRIAL

YOU CAN HELP DEVELOP TREATMENTS TO STOP BREAST CANCER COMING BACK

FIND OUT MORE INFORMATION